| Catalog | Description | Size | Price (USD) | Qty |
|---|---|---|---|---|
| GBM-1102-5MG | Sivelestat | 5mg | $114.00 | |
| GBM-1102-25MG | Sivelestat | 25mg | $462.00 |
| Bioassays Specification | |
| Bio-Activity | Leukocyte elastase inhibitor |
| Chemical Name | N-{2-[({4-[(2,2-Dimethylpropanoyl)oxy]phenyl}sulfonyl)amino]benzoyl}glycine sodium |
| Function / Pharmacology | Potent and selective leukocyte elastase inhibitor, IC50 = 44 nM1. Displays no activity at a variety of other proteases. Inhibits NF-κB activation2 and LTB4-induced neutrophil migration in vitro3. Significantly attenuates ischemia-induced spinal cord injury, decreases serum cytokine levels and reduces acute inflammatory lung injury in vivo4. |
| CAS# | 127373-66-4 |
| MW | 456.45 |
| Molecular Formula | C20H21N2O7 |
| Solubility | Soluble in DMSO (up to 20 mg/ml). |
| Supplied | powder |
| Storage as supplied | RT |
| Ship temp | Ambient |
| References | 1) Kawabata et al. (1991), ONO-5046, a novel inhibitor of human neutrophil elastase; Biochem. Biophys. Res. Commun., 177 814 2) Hagiwara et al. (2009), Neutrophil elastase inhibitor (sivelestat) reduces the levels of inflammatory mediators by inhibiting NFκB; Inflamm. Res., 58 198 3) Young et al. (2007), Role of neutrophil elastase in LTB4-induced neutrophil transmigration in vivo assessed with a specific inhibitor and neutrophil elastase deficient mice; Br. J. Phamracol., 151 628 4) Iwamoto et al. (2009), Protective effect of sivelestat sodium hydrate (ONO-5046) on ischemic spinal cord injury; Interact. Cardiovasc. Thorac. Surg., 8 606 |
| Antibody Specification | |
| Alternate Names | ONO-5046 |
| Protein Specification | |
| Purity | >98% |
| Bioassays Specification | |
| Bio-Activity | Leukocyte elastase inhibitor |
| Chemical Name | N-{2-[({4-[(2,2-Dimethylpropanoyl)oxy]phenyl}sulfonyl)amino]benzoyl}glycine sodium |
| Function / Pharmacology | Potent and selective leukocyte elastase inhibitor, IC50 = 44 nM1. Displays no activity at a variety of other proteases. Inhibits NF-κB activation2 and LTB4-induced neutrophil migration in vitro3. Significantly attenuates ischemia-induced spinal cord injury, decreases serum cytokine levels and reduces acute inflammatory lung injury in vivo4. |
| CAS# | 127373-66-4 |
| MW | 456.45 |
| Molecular Formula | C20H21N2O7 |
| Solubility | Soluble in DMSO (up to 20 mg/ml). |
| Supplied | powder |
| Storage as supplied | RT |
| Ship temp | Ambient |
| References | 1) Kawabata et al. (1991), ONO-5046, a novel inhibitor of human neutrophil elastase; Biochem. Biophys. Res. Commun., 177 814 2) Hagiwara et al. (2009), Neutrophil elastase inhibitor (sivelestat) reduces the levels of inflammatory mediators by inhibiting NFκB; Inflamm. Res., 58 198 3) Young et al. (2007), Role of neutrophil elastase in LTB4-induced neutrophil transmigration in vivo assessed with a specific inhibitor and neutrophil elastase deficient mice; Br. J. Phamracol., 151 628 4) Iwamoto et al. (2009), Protective effect of sivelestat sodium hydrate (ONO-5046) on ischemic spinal cord injury; Interact. Cardiovasc. Thorac. Surg., 8 606 |
| Antibody Specification | |
| Alternate Names | ONO-5046 |
| Protein Specification | |
| Purity | >98% |
